{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:15:35Z","timestamp":1788552935501,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.farma.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:49:53Z","timestamp":1788551393000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Papel actual del cannabis en terap\u00e9utica: una visi\u00f3n cr\u00edtica"],"prefix":"10.1016","author":[{"given":"Eduardo","family":"L\u00f3pez Briz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Majem Tarruella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Pitarch Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"de Santiago Moraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Smeyers Dur\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.farma.2026.08.002_bb0005","series-title":"The analytical chemistry of Cannabis. Quality assessment, assurance, and regulation of medicinal marijuana and cannabinoid preparations","author":"Thomas","year":"2016"},{"key":"10.1016\/j.farma.2026.08.002_bb0010","unstructured":"Informe de la Subcomisi\u00f3n al objeto de analizar experiencias de regulaci\u00f3n del cannabis para uso medicinal. Bolet\u00edn Oficial de las Cortes Generales. Congreso de los Diputados. [consultado 14 Abr 2026]. Disponible en: https:\/\/pnsd.sanidad.gob.es\/profesionales\/cannabis\/PaisesRegulados\/Espana\/pdf\/20220705_InformeSubcomisionCannabisMedicinal_BOCG_Serie_D__2022.pdf."},{"key":"10.1016\/j.farma.2026.08.002_bb0015","first-page":"129493","article-title":"Real Decreto 903\/2025, de 7 de octubre, por el que se establecen las condiciones Para la elaboraci\u00f3n y dispensaci\u00f3n de f\u00f3rmulas magistrales tipificadas de preparados estandarizados de cannabis","year":"2025","journal-title":"Bolet\u00edn Oficial del Estado, n\u00fam 243, 9 de octubre de"},{"key":"10.1016\/j.farma.2026.08.002_bb0020","unstructured":"FN\/2026\/FMT\/043 Preparado estandarizado de cannabis (THC, CBD) soluci\u00f3n oral. [consultado 14 Abr 2026]. Disponible en: https:\/\/www.aemps.gob.es\/formulario-nacional\/monografias\/formulas-magistrales-tipificadas\/fn_2026_fmt_043.pdf."},{"key":"10.1016\/j.farma.2026.08.002_bb0025","unstructured":"Posicionamiento de la Sociedad Espa\u00f1ola de Farmacia Hospitalaria Sobre el Real Decreto de cannabis Medicinal. Madrid, febrero de 2026. [consultado 14 Abr 2026]. Disponible en: https:\/\/www.sefh.es\/bibliotecavirtual\/posicionamientos_institucionales\/15-posicionamiento-sefh-real-decreto-cannabis-medicinal.pdf."},{"issue":"6","key":"10.1016\/j.farma.2026.08.002_bb0030","first-page":"607","article-title":"Review of the endocannabinoid system","volume":"6","author":"Lu","year":"2021","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"6","key":"10.1016\/j.farma.2026.08.002_bb0035","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/187152709789824660","article-title":"The endocannabinoid system and pain","volume":"8","author":"Guindon","year":"2009","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.farma.2026.08.002_bb0040","article-title":"Cannabis-based medicines for chronic neuropathic pain in adults","volume":"1","author":"Ate\u015f","year":"2026","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.farma.2026.08.002_bb0045","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1038\/s41591-025-03977-0","article-title":"Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial","volume":"31","author":"Karst","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.farma.2026.08.002_bb0050","first-page":"CD014915","article-title":"Cannabis-based medicines and medical cannabis for adults with cancer pain","volume":"6","author":"H\u00e4user","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.farma.2026.08.002_bb0055","article-title":"Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomized clinical trials","volume":"373","author":"Wang","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.farma.2026.08.002_bb0060","article-title":"Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline","volume":"374","author":"Busse","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.farma.2026.08.002_bb0065","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1037\/pha0000795","article-title":"Looking beyond traditional pain outcomes to better evaluate cannabis's true potential and limitations in chronic pain management","volume":"33","author":"Mun","year":"2025","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1016\/j.farma.2026.08.002_bb0070","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/ejp.1297","article-title":"European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management","volume":"22","author":"H\u00e4user","year":"2018","journal-title":"Eur J Pain"},{"key":"10.1016\/j.farma.2026.08.002_bb0075","unstructured":"Posicionamiento de la SED respecto a la utilizaci\u00f3n del Cannabis medicinal en el tratamiento del dolor. Junio 2022. Sociedad Espa\u00f1ola del Dolor. [consultado 4 Jul 2026]. Disponible en: https:\/\/sedolor.es\/posicionamiento-sed-utilizacion-cannabis-medicinal-en-tratamiento-dolor-junio-2022\/."},{"issue":"24","key":"10.1016\/j.farma.2026.08.002_bb0080","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.farma.2026.08.002_bb0085","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1200\/JCO.23.02596","article-title":"Cannabis and cannabinoids in adults with cancer: ASCO guideline","volume":"42","author":"Braun","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.farma.2026.08.002_bb0090","first-page":"2095","article-title":"Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting. A systematic review and meta-analysis","volume":"28","author":"Chow","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.farma.2026.08.002_bb0095","article-title":"Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy","volume":"11","author":"Smith","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.farma.2026.08.002_bb0100","first-page":"39","article-title":"Multinational Association of Supportive Care in Cancer (MASCC) expert opinion\/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in patients with cancer","volume":"31","author":"Alderman","year":"2022","journal-title":"Support Care Cancer"},{"issue":"34","key":"10.1016\/j.farma.2026.08.002_bb0105","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1200\/JCO.23.01836","article-title":"Oral cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: final results of a randomized, placebo-controlled, phase II\/III trial","volume":"42","author":"Grimison","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.farma.2026.08.002_bb0110","article-title":"Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis","volume":"5","author":"Filippini","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.farma.2026.08.002_bb0115","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1089\/can.2022.0254","article-title":"Effectiveness and safety of cannabinoids as an add-on therapy in the treatment of resistant spasticity in multiple sclerosis: a systematic review","volume":"8","author":"Martinez-Paz","year":"2023","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"10.1016\/j.farma.2026.08.002_bb0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clinthera.2025.07.009","article-title":"Assessing the role of cannabis in managing spasticity in multiple sclerosis: a systematic review and meta-analysis","volume":"48","author":"AlHabil","year":"2026","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.farma.2026.08.002_bb0125","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3390\/ph16081079","article-title":"Cannabis-based medicine for neuropathic pain and spasticity-a multicenter, randomized, double-blinded, placebo-controlled trial","volume":"16","author":"Hansen","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.farma.2026.08.002_bb0130","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-072348","article-title":"Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies","volume":"382","author":"Solmi","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.farma.2026.08.002_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115665","article-title":"Mechanisms of cannabinoid tolerance","volume":"214","author":"Piscura","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"10.1016\/j.farma.2026.08.002_bb0140","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1007\/s00586-024-08362-y","article-title":"Cannabis use by individuals with spinal cord injury in the UK: a call for improved patient education and physician awareness for pain and spasticity management","volume":"33","author":"Anas","year":"2024","journal-title":"Eur Spine J"},{"key":"10.1016\/j.farma.2026.08.002_bb0145","unstructured":"Evidence review for spasticity: cannabis-based medicinal products. Evidence review C. National Institute for Health and Care Excellence (NICE); 2019. (NICE guideline, no. 144). [consultado 14 Abr 2026]. Disponible en: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK577084\/."},{"issue":"6","key":"10.1016\/j.farma.2026.08.002_bb0150","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.3390\/ijms23063344","article-title":"Cannabinoids: therapeutic use in clinical practice","volume":"23","author":"Pagano","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.farma.2026.08.002_bb0155","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1056\/NEJMra1407304","article-title":"Cannabinoids in the treatment of epilepsy","volume":"373","author":"Friedman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.farma.2026.08.002_bb0160","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13311-015-0375-5","article-title":"Cannabinoids and epilepsy","volume":"12","author":"Rosenberg","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1016\/j.farma.2026.08.002_bb0165","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.farma.2026.08.002_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.586110","article-title":"Cannabidiol treatment for refractory epilepsies in pediatrics","volume":"11","author":"Raucci","year":"2020","journal-title":"Front Pharmacol"},{"issue":"21","key":"10.1016\/j.farma.2026.08.002_bb0175","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.farma.2026.08.002_bb0180","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.farma.2026.08.002_bb0185","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.farma.2026.08.002_bb0190","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.farma.2026.08.002_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114238","article-title":"Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: a systematic review and meta-analysis","volume":"359","author":"Talwar","year":"2023","journal-title":"Exp Neurol"},{"issue":"3","key":"10.1016\/j.farma.2026.08.002_bb0200","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40263-021-00807-y","article-title":"Highly purified cannabidiol for epilepsy treatment: a systematic review of epileptic conditions beyond Dravet syndrome and Lennox\u2013Gastaut syndrome","volume":"35","author":"Lattanzi","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.farma.2026.08.002_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109330","article-title":"The use of cannabinoids in children with epilepsy: a systematic review","volume":"145","author":"Da Silva Rodrigues","year":"2023","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.farma.2026.08.002_bb0210","doi-asserted-by":"crossref","first-page":"203","DOI":"10.25259\/JNRP_618_2023","article-title":"Use of cannabidiol in the treatment of drug-refractory epilepsy in children and young adults: a systematic review","volume":"15","author":"Vargas Chico","year":"2024","journal-title":"J Neurosci Rural Pract"},{"key":"10.1016\/j.farma.2026.08.002_bb0215","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant epilepsies","volume":"54","author":"Laux","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.farma.2026.08.002_bb0220","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251313914","article-title":"The use of cannabidiol as adjunctive therapy in adult patients with drug-resistant epilepsy: a systematic review and meta-analysis","volume":"18","author":"Ong","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.farma.2026.08.002_bb0225","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1684\/epd.2021.1244","article-title":"Developmental and epileptic encephalopathies: recognition and approaches to care","volume":"23","author":"Raga","year":"2021","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.farma.2026.08.002_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107280","article-title":"Caregiver-reported outcomes with real-world use of cannabidiol in Lennox-Gastaut syndrome and Dravet syndrome from the BECOME survey","volume":"200","author":"Berg","year":"2024","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.farma.2026.08.002_bb0235","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/imj.70094","article-title":"Medicinal cannabis: is current use clinically justified?","volume":"55","author":"Scott","year":"2025","journal-title":"Intern Med J"},{"issue":"2","key":"10.1016\/j.farma.2026.08.002_bb0240","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/jcsm.12273","article-title":"Systematic review an meta-analysis of cannabinoids in palliative medicine","volume":"9","author":"M\u00fcck","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.farma.2026.08.002_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100092","article-title":"Cancer cachexia in adult patients: ESMO clinical practice guidelines","volume":"6","author":"Arends","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.farma.2026.08.002_bb0250","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1186\/s12916-022-02459-1","article-title":"Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications","volume":"20","author":"Bilbao","year":"2022","journal-title":"BMC Med"},{"issue":"5","key":"10.1016\/j.farma.2026.08.002_bb0255","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/01.ijg.0000212260.04488.60","article-title":"Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study","volume":"15","author":"Tomida","year":"2006","journal-title":"J Glaucoma"},{"issue":"1","key":"10.1016\/j.farma.2026.08.002_bb0260","first-page":"93","article-title":"C\u00e1nnabis, cannabinoides y glaucoma: \u00bfcu\u00e1nto ruido y cu\u00e1ntas nueces?","volume":"42","author":"L\u00f3pez Briz","year":"2017","journal-title":"Rev Esp Drogodependencias"},{"issue":"1","key":"10.1016\/j.farma.2026.08.002_bb0265","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/imr.2024.0017","article-title":"Evaluating the current evidence for the efficacy of cannabis in symptom management of endometriosis-associated pain","volume":"3","author":"Calleson Cummings","year":"2024","journal-title":"Integr Med Rep"},{"issue":"5","key":"10.1016\/j.farma.2026.08.002_bb0270","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00213-021-05855-2","article-title":"Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21","volume":"239","author":"Sakal","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.farma.2026.08.002_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2025.116552","article-title":"Medicinal cannabis in the management of anxiety disorders: a systematic review","volume":"350","author":"Roberts","year":"2025","journal-title":"Psychiatry Res"},{"issue":"4","key":"10.1016\/j.farma.2026.08.002_bb0280","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jama.2025.19433","article-title":"Therapeutic use of cannabis and cannabinoids: a review","volume":"335","author":"Hsu","year":"2026","journal-title":"JAMA"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001832?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326001832?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:49:59Z","timestamp":1788551399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326001832"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":56,"alternative-id":["S1130634326001832"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.08.002","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Papel actual del cannabis en terap\u00e9utica: una visi\u00f3n cr\u00edtica","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}